BioSight Ltd.

www.biosight-pharma.com

High-Tech Company

Acquired by Ayala Pharmaceuticals

Graduated from: Trendlines Incubators

TAGS

Oncology, Therapeutics

General Data

Sector	Life Sciences
Sub-Sector	Pharmaceuticals

TECHNOLOGY

Aspacytarabine (BST-236) is a novel pro-drug of the chemotherapeutic drug cytarabine. Cytarabine has been the backbone of first-line therapy for AML for the past 40 years, however, it is associated with severe bone marrow, gastrointestinal,...(Unlock More)...

CONTACT INFO

Personal Contact Information

Blog

Expand / Collapse All

	MANAGEMENT

Key Executive

	BOARD

Board

	FINANCIAL ROUNDS

Round

Date

Stage

Amount

Valuation

Third Round - Extended

Dec. 02, 2020

R&D

$27m

$115m

General Info

Angel Company & Title
E-mail
Website
No. of Current Portfolio Companies
Remarks

Business Description

Description
Angel Activity

Investment Data

Managed Capital
Capital Remarks
Capital Available

Preferences

Maximum investments
Minimum investments
Type of Financing
Stage Preferences
Phase Preferences
Industry Preferences

	SECTOR SEGMENTATION (By Number Of Companies)

Current Israeli Clients (#)

	Deals Underwritten (#)

	Deals Legally Advised (#)

	Current Positions

	Previous Positions

	Background

	Education

	Specialties

Last Updated: Jul 27, 2023